Dogwood Therapeutics, INC 8-K filings

Dogwood Therapeutics announced its second quarter 2026 financial results, highlighting progress in its Halneuron Phase 2b trial and a new development partnership, while also reporting a substantial non-cash impairment charge.

Dogwood Therapeutics, Inc. announced the outcomes of its annual stockholder meeting, including the approval of amendments to its Certificate of Incorporation and the election of directors.

Dogwood Therapeutics announced Q1 2026 results, highlighting progress in Halneuron and SP16 clinical trials, an FDA IND acceptance, and a new global development partnership for legacy assets.

Dogwood Therapeutics reports significant progress in its non-opioid pain and neuropathy pipeline, including patient recruitment, a $12.5 million capital raise, and new IND filings.

Dogwood Therapeutics announced its Q4 and full year 2025 financial results, highlighting progress in its Halneuron Phase 2b trial and recent financing.

Dogwood Therapeutics, Inc. announced that its shareholders approved the potential exercise of an unregistered common stock warrant for up to 4,386,037 shares and the issuance of common stock.

Dogwood Therapeutics provides a corporate update, highlighting 2025 progress in its non-opioid pain and neuropathy pipeline and outlining key 2026 milestones.

Dogwood Therapeutics, Inc. announced a registered direct offering and concurrent private placement, raising $12.5 million upfront with potential for an additional $14.4 million from warrant exercises to fund its clinical pipeline.

Dogwood Therapeutics, Inc. has entered into an Equity Distribution Agreement to sell up to $8.56 million of common stock through an at-the-market offering.

Dogwood Therapeutics stockholders approved an expanded equity incentive plan and the conversion of preferred stock, finalizing its business combination with Sealbond Limited.

Dogwood Therapeutics reported a significant increase in its third-quarter net loss to $15.7 million, driven by R&D expenses for a new cancer pain treatment, SP16, while its lead drug Halneuron's Phase 2b trial progresses.

Dogwood Therapeutics provides a Q4 2025 update, highlighting progress in its Halneuron and SP16 programs for cancer-related neuropathy and pain.

Dogwood Therapeutics has acquired an exclusive, royalty-free global license for Serpin Pharma's SP16, an LRP1 agonist for chemotherapy-induced peripheral neuropathy, in an all-stock transaction.

Dogwood Therapeutics reported an increased net loss in Q2 2025, driven by higher R&D and G&A expenses, while advancing its Halneuron Phase 2b trial and pausing IMC-2 Long-COVID research.

Dogwood Therapeutics, Inc. announced a base salary increase for Chief Financial Officer Angela Walsh to $321,903 annually, effective July 1, 2025, following a review of peer company compensation.

Dogwood Therapeutics, Inc. announced that its stockholders approved an amendment to the company's equity incentive plan, increasing the shares reserved for issuance, and elected seven directors at its annual meeting held on June 18, 2025.

Dogwood Therapeutics reports Q1 2025 financial results, highlights the commencement of dosing in its Halneuron Phase 2b CINP study, and anticipates interim data in Q4 2025.

Dogwood Therapeutics believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a debt exchange and stock offering.

Dogwood Therapeutics reports Q4 and full-year 2024 financial results, highlights clinical trial progress, and announces a strengthened balance sheet.

Dogwood Therapeutics secures $4.8 million through a registered direct offering to advance clinical development of Halneuron and for general corporate purposes.

Dogwood Therapeutics converts $19.5 million in debt to equity with its largest shareholder, CK Life Sciences, strengthening its balance sheet and investment appeal.

Dogwood Therapeutics, formerly Virios Therapeutics, has finalized its acquisition of Pharmagesic, a move that brings a promising non-opioid pain treatment into its portfolio.

Dogwood Therapeutics has received a notification from Nasdaq that it no longer meets the minimum stockholders' equity requirement for continued listing.

Dogwood Therapeutics reported its third quarter 2024 financial results, highlighting a pipeline expansion and strategic financing to support operations through 2025.

Dogwood Therapeutics has regained compliance with Nasdaq's minimum bid price requirement and is anticipating key clinical trial results.

Virios Therapeutics and Wex Pharmaceuticals have merged to create Dogwood Therapeutics, a company focused on developing treatments for pain and viral-related diseases, backed by a $19.5 million financing.

Virios Therapeutics reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a Long-COVID phase 2a study and a recent capital raise.

Virios Therapeutics successfully held its annual meeting, electing six directors and ratifying the appointment of FORVIS, LLP as its independent auditor for the fiscal year ending December 31, 2024.

Virios Therapeutics has received an extension until October 28, 2024, to meet Nasdaq's minimum bid price requirement, with a potential reverse stock split if compliance is not achieved by October 11, 2024.

Virios Therapeutics has announced the pricing of a $1.7 million public offering of common stock to support preparations for a Phase 2b study on Long-COVID.